Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04777-z
Abstract: Dear Editor, Venetoclax is an oral drug that is BH3-mimetic and a selective B-cell lymphoma 2 (BCL-2) inhibitor. Inhibition of BCL-2 induces apoptosis in hematological malignancies [1]. Venetoclax has shown activity in patients with acute… read more here.
Keywords: response; therapy related; aml; mds aml ... See more keywords
Role of p53 in regulation of hematopoiesis in health and disease
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Hematology"
DOI: 10.1097/moh.0000000000000715
Abstract: Purpose of review Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and… read more here.
Keywords: tp53 mutations; mutant p53; p53; hematopoiesis ... See more keywords
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16710
Abstract: In this issue, M€ uller-Thomas et al. explored the predictive value of indoleamine 2,3 dioxygenase (IDO) expression in 96 patients with high-risk myelodysplastic syndromes (MDS) and secondary AML (sAML) treated with azacitidine. MDS are clonal… read more here.
Keywords: ido; mds; mds aml; disease progression ... See more keywords
GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18330
Abstract: The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called “myeloid neoplasms with germline predisposition”. A major… read more here.
Keywords: mds; deficiency mds; gata2 deficiency; aml experimental ... See more keywords
Abstract 127: Efficacy of novel IRAK4 inhibitor CA4948 in AML and MDS
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-127
Abstract: Myelodysplastic syndrome (MDS) & Acute Myeloid Leukemia (AML) are hematologic malignancies that arise from a population of aberrant hematopoietic stem cells (HSCs). Overactivated innate immune signaling pathways such as IRAK1, TRAF6, IL1RAP, S100A9 and IL8… read more here.
Keywords: inhibitor; mds aml; efficacy; mds ... See more keywords
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Sign Up to like & getrecommendations! Published in 2023 at "Blood"
DOI: 10.1182/blood.2022018718
Abstract: Dysregulation of innate immune signaling is a hallmark of hematologic malignancies. Recent therapeutic efforts to subvert aberrant innate immune signaling in MDS and AML have focused on the kinase IRAK4. IRAK4 inhibitors have achieved promising,… read more here.
Keywords: mds aml; myd88 independent; irak4; irak1 irak4 ... See more keywords
Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.7035
Abstract: 7035 Background: Myeloablative allogeneic hematopoietic cell transplantation (AHCT) is potentially curative for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but toxicities of conditioning limit its use in older or frail patients. Non-myeloablative (NMA) conditioning… read more here.
Keywords: jsp191; older adults; cell; mds aml ... See more keywords
A Phase 1 Study of IRX195183, a RARα-Selective CYP26 Resistant Retinoid, in Patients With Relapsed or Refractory AML
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2020.587062
Abstract: Subsets of non-acute promyelocytic leukemia (APL) acute myelogenous leukemia (AML) exhibit aberrant retinoid signaling and demonstrate sensitivity to retinoids in vitro. We present the results of a phase 1 dose-escalation study that evaluated the safety,… read more here.
Keywords: relapsed refractory; mds aml; study; retinoid ... See more keywords
A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.844978
Abstract: Aim Bone marrow biopsy is essential and necessary for the diagnosis of patients with aplastic anemia (AA), myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). However, the convolutional neural networks (CNN) model that automatically distinguished… read more here.
Keywords: classification; bone marrow; mds aml; model ... See more keywords
The Differential Expression of CD47 may be Related to the Pathogenesis From Myelodysplastic Syndromes to Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.872999
Abstract: Myelodysplastic syndrome (MDS) can lead to the development of peripheral blood cytopenia and abnormal cell morphology. MDS has the potential to evolve into AML and can lead to reduced survival. CD47, a member of the… read more here.
Keywords: expression; differential expression; cd47; mds aml ... See more keywords
Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.912256
Abstract: Background and purpose: poly-ADP ribose polymerase (PARP) inhibitors show impressive efficacy in a range of tumors. However, concerns about rare and fatal adverse events, including myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML) have arisen.… read more here.
Keywords: mds aml; parp inhibitors; real world;